Licensing revenues at Nationwide Children’s Hospital fell from $36.7m in 2017, though the hospital is reportedly projecting turnover of at least $25m for the first quarter of 2019.
Nationwide Children’s Hospital, an affiliate of Ohio State University, generated $11.5m in revenue in 2018 from technology licensing agreements struck by its tech transfer office (TTO), Office of Technology Commercialization (OTC).
The figure is down from the record $36.7m the hospital booked in 2017, according to Columbus Business First, but it is expected to take in more than $25m in the first quarter of 2019 from deals including the sale of its gene therapy spinout Myonexus Therapeutics in February.
Nationwide’s TTO completed 19 licensing deals in 2018, compared with 18 in 2018, and registered 94 inventions by its researchers. A decade ago, the hospital processed approximately 20 inventions and concluded commercialisation agreements for two technologies.
Nationwide Children’s Hospital believes further opportunities for tech transfer could arise from industry looking to Ohio and the US Midwest as a “fertile” landscape for commercialisation, according to OTC director Matt McFarland.
McFarland said: “The research enterprise that goes on here is pretty big, and when we have innovations that could benefit the greater good, we should do our best to transfer that into the public sector. As a research institute, to attract the best and brightest in their fields, we need to have this capability fully developed and competitive.”
